digraph structs {
rankdir=LR;
g0 [shape=record,label="http://dikb.org/object-dr\lug-role/20bb65b1-1ed2-494\ld-bda7-fd24a4941a15\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g1 [shape=record,label="http://purl.obolibrary.or\lg/obo/UO_0000187\l\lrdfs:Class\l",color=blue]
g2 [shape=record,label="http://purl.obolibrary.or\lg/obo/PATO_0000125\l\lrdfs:Class\l",color=blue]
g3 [shape=record,label="http://dikb.org/precipita\lnt-active-ingredient/ddab\lfb74-b457-4c04-b8ea-a0b6f\l61c030c\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g4 [shape=record,label="http://dikb.org/precipita\lnt-drug-role/2eb00f1a-acb\le-4379-a2c3-f589c16059de\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g5 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0000576\l\lrdfs:Class\l",color=blue]
g6 [shape=record,label="http://dikb.org/object-va\llue-measurement-datum/6e2\l99f72-b98b-4b52-8a94-eed5\l9191f0be\l\lobo:IAO_0000109\l",color=blue]
g6 -> g57 [label="has specified value\lobo:OBI_0001937\l"]
g6 -> g42 [label="\lobo:IAO_0000221\l"]
g7 [shape=record,label="http://purl.obolibrary.or\lg/obo/UO_0000022\l\lrdfs:Class\l",color=blue]
g8 [shape=record,label="http://dikb.org/object-mi\llligram/e2105ee8-c829-431\l0-9fde-52db6f2387ac\l\lobo:UO_0000022\l",color=blue]
g9 [shape=record,label="http://dikb.org/method/80\l01a4b8-a2bf-4586-a0a6-885\leff89ea12\l\lobo:DIDEO_00000124\l|label\lrdfs:label\lnefazodone-digoxin DDI cl\linical trial\l",color=blue]
g10 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000136\l\lrdf:Property\l",color=blue]
g11 [shape=record,label="http://dikb.org/precipita\lnt-value-specification/aa\l224600-6edd-42c8-9ba3-b14\le5ed1b0a2\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l200\l",color=blue]
g11 -> g34 [label="\lobo:IAO_0000039\l"]
g12 [shape=record,label="http://dikb.org/object-ma\lss/01ed047a-5912-403c-8f9\l5-5487ea3bddd7\l\lobo:PATO_0000125\l",color=blue]
g13 [shape=record,label="http://dikb.org/data-rati\lo-type/3591beac-135e-4453\l-ba73-f745a9388d0c\lvalue specification\lobo:OBI_0001933\l|label\lrdfs:label\l50 Percent \l",color=blue]
g13 -> g17 [label="\lobo:OBI_0000051\l"]
g14 [shape=record,label="http://purl.obolibrary.or\lg/obo/BFO_0000051\l\lrdf:Property\l",color=blue]
g15 [shape=record,label="http://dikb.org/precipita\lnt-mass/234c4770-2d9c-409\l2-9d14-4210dda9bd48\l\lobo:PATO_0000125\l",color=blue]
g16 [shape=record,label="http://dikb.org/data-rati\lo-type/d26301d0-14ba-4ce8\l-9321-f109a9f32970\lvalue specification\lobo:OBI_0001933\l|label\lrdfs:label\l50 Percent \l",color=blue]
g16 -> g48 [label="\lobo:OBI_0000051\l"]
g17 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/ecbd7362-\lff18-46d0-ac3c-a1ed10d40c\l2d\lpercent\lobo:UO_0000187\l",color=blue]
g18 [shape=record,label="http://www.w3.org/1999/02\l/22-rdf-syntax-ns#type\l\lrdf:Property\l",color=blue]
g19 [shape=record,label="http://dikb.org/object-ac\ltive-ingredient/2156ec05-\l1fb6-44ac-9bdf-9f6ada3fce\l0e\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g20 [shape=record,label="http://dikb.org/bearer-ob\lject/876167ba-abfb-4a95-a\l5f6-4a487b573433\l",color=orange]
g20 -> g0 [label="\lobo:RO_0000053\l"]
g20 -> g70 [label="has part\lobo:BFO_0000051\l"]
g21 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/51296759-\l828e-4f93-a9c6-0aacff9b25\l30\lpercent\lobo:UO_0000187\l",color=blue]
g22 [shape=record,label="http://dikb.org/precipita\lnt-value-specification/45\l0406de-5c43-48c7-bee9-a1a\l1bc54e75c\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l1000\l",color=blue]
g22 -> g27 [label="\lobo:IAO_0000039\l"]
g23 [shape=record,label="http://dikb.org/data-rati\lo-type/f3c325be-d13f-4933\l-becd-7e7f65a63698\lvalue specification\lobo:OBI_0001933\l|label\lrdfs:label\l29 Percent \l",color=blue]
g23 -> g21 [label="\lobo:OBI_0000051\l"]
g24 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0000312\l\lrdf:Property\l",color=blue]
g25 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000039\l\lrdf:Property\l",color=blue]
g26 [shape=record,label="http://dikb.org/object-dr\lug/6e74686c-bfc7-464e-ae0\l7-d068a739fc46\l\l\<obo:RxNorm_686438\>\l",color=blue]
g27 [shape=record,label="http://dikb.org/precipita\lnt-milligram/3de9e5e2-59c\l8-41fd-a2ac-e33b3eef2df9\l\lobo:UO_0000022\l",color=blue]
g28 [shape=record,label="http://dikb.org/precipita\lnt-drug-role/5dd2dced-99f\l8-47c8-9062-046ac4bcc24c\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g29 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000124\l\lrdfs:Class\l",color=blue]
g30 [shape=record,label="http://dikb.org/data-rati\lo/7a10e091-b0b4-4ba0-984c\l-d8b3d008dc45\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\lnefazodone-digoxin drug p\lackage cmax Increase info\lrmation\l",color=blue]
g30 -> g9 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g30 -> g23 [label="has specified value\lobo:OBI_0001937\l"]
g31 [shape=record,label="http://dikb.org/precipita\lnt-active-ingredient/b4c3\l830d-76f2-49cf-9c5c-94110\lda4432e\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g32 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/32adbe1c-\l91cf-4457-aa55-895672bbca\l25\lpercent\lobo:UO_0000187\l",color=blue]
g33 [shape=record,label="http://purl.obolibrary.or\lg/obo/RO_0002351\l\lrdf:Property\l",color=blue]
g34 [shape=record,label="http://dikb.org/precipita\lnt-milligram/957cc4b4-84d\lf-4698-884d-ea23c808fe36\l\lobo:UO_0000022\l",color=blue]
g35 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000001\l\lrdfs:Class\l",color=blue]
g36 [shape=record,label="http://dikb.org/p-scatter\led-molecular-aggregate/98\l9f30d1-dd2f-4837-bd46-f4f\lb430545d4\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g36 -> g66 [label="\lobo:RO_0000053\l"]
g36 -> g31 [label="\lobo:RO_0000053\l"]
g36 -> g56 [label="\lobo:RO_0002351\l"]
g37 [shape=record,label="http://dikb.org/bearer-pr\lecipitant/4a9715be-e71f-4\l9f6-b6e2-ba7109ca7bb4\l",color=orange]
g37 -> g63 [label="has part\lobo:BFO_0000051\l"]
g37 -> g28 [label="\lobo:RO_0000053\l"]
g38 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000221\l\lrdf:Property\l",color=blue]
g39 [shape=record,label="http://dikb.org/bearer-pr\lecipitant/698e916c-4755-4\la4d-a08b-a753368a25e1\l",color=orange]
g39 -> g36 [label="has part\lobo:BFO_0000051\l"]
g39 -> g4 [label="\lobo:RO_0000053\l"]
g40 [shape=record,label="http://dikb.org/object-va\llue-measurement-datum/e7a\l19131-becb-416e-bd93-08e0\la175692c\l\lobo:IAO_0000109\l",color=blue]
g40 -> g12 [label="\lobo:IAO_0000221\l"]
g40 -> g55 [label="has specified value\lobo:OBI_0001937\l"]
g41 [shape=record,label="http://dikb.org/method/99\l9a7d05-deb7-480c-8935-265\l315282188\l\lobo:DIDEO_00000124\l|label\lrdfs:label\ldivalproex sodium-INVEGA \lDDI clinical trial\l",color=blue]
g42 [shape=record,label="http://dikb.org/object-ma\lss/72d2630c-1c06-4ce6-a24\l1-e43d58463a6e\l\lobo:PATO_0000125\l",color=blue]
g43 [shape=record,label="http://dikb.org/data-rati\lo/5c996a80-e2fb-4aa2-b6a1\l-22cc9c265559\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\ldivalproex sodium-INVEGA \ldrug package cmax Increas\le information\l",color=blue]
g43 -> g41 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g43 -> g16 [label="has specified value\lobo:OBI_0001937\l"]
g44 [shape=record,label="http://dikb.org/assertion\l/d5884b02-48b2-48de-9288-\l5de77a77d2b1\ldrug-drug interaction des\lcription\lobo:DIDEO_00000001\l|label\lrdfs:label\ldivalproex sodium-INVEGA \linteraction description\l",color=blue]
g44 -> g43 [label="has part\lobo:BFO_0000051\l"]
g44 -> g53 [label="\lobo:IAO_0000136\l"]
g44 -> g39 [label="\lobo:IAO_0000136\l"]
g44 -> g46 [label="has part\lobo:BFO_0000051\l"]
g45 [shape=record,label="http://dikb.org/o-scatter\led-molecular-aggregate/4d\l429d20-be93-4fe1-a1f9-c02\l77b608db1\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g45 -> g19 [label="\lobo:RO_0000053\l"]
g45 -> g26 [label="\lobo:RO_0002351\l"]
g45 -> g40 [label="\lobo:RO_0000053\l"]
g46 [shape=record,label="http://dikb.org/data-rati\lo/d623b3f0-32ff-4091-9621\l-74f0a22e9990\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\ldivalproex sodium-INVEGA \ldrug package auc Increase\l information\l",color=blue]
g46 -> g41 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g46 -> g13 [label="has specified value\lobo:OBI_0001937\l"]
g47 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0001933\l\lrdfs:Class\l",color=blue]
g48 [shape=record,label="http://dikb.org/data-rati\lo-type-has-part/a38ba9ca-\ld92d-4881-940f-9e979813cb\lea\lpercent\lobo:UO_0000187\l",color=blue]
g49 [shape=record,label="http://dikb.org/object-dr\lug/0811409f-a236-4ea9-83d\l4-22dbc5773cce\l\l\<obo:RxNorm_3407\>\l",color=blue]
g50 [shape=record,label="http://www.w3.org/2000/01\l/rdf-schema#label\l\lrdf:Property\l",color=blue]
g51 [shape=record,label="http://dikb.org/object-mi\llligram/1a0cae88-998e-490\lc-b50f-59c754eb941f\l\lobo:UO_0000022\l",color=blue]
g52 [shape=record,label="http://dikb.org/precipita\lnt-value-measurement-datu\lm/25d7a0aa-9f5e-4c57-b878\l-c333d6b319e0\l\lobo:IAO_0000109\l",color=blue]
g52 -> g61 [label="\lobo:IAO_0000221\l"]
g52 -> g11 [label="has specified value\lobo:OBI_0001937\l"]
g53 [shape=record,label="http://dikb.org/bearer-ob\lject/c4637584-36d5-4812-b\lc6a-2977d6f23966\l",color=orange]
g53 -> g45 [label="has part\lobo:BFO_0000051\l"]
g53 -> g59 [label="\lobo:RO_0000053\l"]
g54 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0001937\l\lrdf:Property\l",color=blue]
g55 [shape=record,label="http://dikb.org/object-va\llue-specification/a8f237e\ld-dda0-4356-a74c-bd04d84a\le32b\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l12\l",color=blue]
g55 -> g8 [label="\lobo:IAO_0000039\l"]
g56 [shape=record,label="http://dikb.org/precipita\lnt-drug/60952425-0d9b-4e0\lb-bfb4-b0b7f342666b\l\l\<obo:MeSH_D014635\>\l",color=blue]
g57 [shape=record,label="http://dikb.org/object-va\llue-specification/57d7841\lc-5a21-47b1-8c45-866a07ba\l809f\lvalue specification\lobo:OBI_0001933\l|has specified value\lobo:OBI_0001937\l.2\l",color=blue]
g57 -> g51 [label="\lobo:IAO_0000039\l"]
g58 [shape=record,label="http://dikb.org/data-rati\lo/70a1c37f-f09f-498a-bad0\l-d8934d9c79bf\linformation about increas\le of pharmacokinetic area\l under the curve\lobo:DIDEO_00000050\l|label\lrdfs:label\lnefazodone-digoxin drug p\lackage auc Increase infor\lmation\l",color=blue]
g58 -> g9 [label="is_specified_output_of\lobo:OBI_0000312\l"]
g58 -> g60 [label="has specified value\lobo:OBI_0001937\l"]
g59 [shape=record,label="http://dikb.org/object-dr\lug-role/e4a020f8-6edc-439\le-9773-7af8a69dada1\lprecipitant drug role\lobo:DIDEO_00000013\l",color=blue]
g60 [shape=record,label="http://dikb.org/data-rati\lo-type/fc1572d1-1f81-433a\l-9e2f-9256608dd279\lvalue specification\lobo:OBI_0001933\l|label\lrdfs:label\l15 Percent \l",color=blue]
g60 -> g32 [label="\lobo:OBI_0000051\l"]
g61 [shape=record,label="http://dikb.org/precipita\lnt-mass/141978d2-0226-4e4\la-b002-ffdf25ee9521\l\lobo:PATO_0000125\l",color=blue]
g62 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000013\l\lrdfs:Class\l",color=blue]
g63 [shape=record,label="http://dikb.org/p-scatter\led-molecular-aggregate/ab\lae99ab-abd3-4e98-94ce-13c\l2e98d528f\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g63 -> g3 [label="\lobo:RO_0000053\l"]
g63 -> g68 [label="\lobo:RO_0002351\l"]
g63 -> g52 [label="\lobo:RO_0000053\l"]
g64 [shape=record,label="http://purl.obolibrary.or\lg/obo/DRON_00000028\l\lrdfs:Class\l",color=blue]
g65 [shape=record,label="http://dikb.org/object-ac\ltive-ingredient/4c3c4772-\l9a84-4a65-aeca-7c089d401f\la4\lactive ingredient\lobo:DRON_00000028\l",color=blue]
g66 [shape=record,label="http://dikb.org/precipita\lnt-value-measurement-datu\lm/25aec3b5-50d7-4aee-8cc3\l-946543bb79a0\l\lobo:IAO_0000109\l",color=blue]
g66 -> g22 [label="has specified value\lobo:OBI_0001937\l"]
g66 -> g15 [label="\lobo:IAO_0000221\l"]
g67 [shape=record,label="http://dikb.org/assertion\l/fe49ee63-2bc3-4459-9177-\l8010a71ae019\ldrug-drug interaction des\lcription\lobo:DIDEO_00000001\l|label\lrdfs:label\lnefazodone-digoxin intera\lction description\l",color=blue]
g67 -> g30 [label="has part\lobo:BFO_0000051\l"]
g67 -> g58 [label="has part\lobo:BFO_0000051\l"]
g67 -> g37 [label="\lobo:IAO_0000136\l"]
g67 -> g20 [label="\lobo:IAO_0000136\l"]
g68 [shape=record,label="http://dikb.org/precipita\lnt-drug/3649309e-7422-499\l1-bd8e-c65e8a51a44b\l\l\<obo:RxNorm_31565\>\l",color=blue]
g69 [shape=record,label="http://purl.obolibrary.or\lg/obo/OBI_0000051\l\lrdf:Property\l",color=blue]
g70 [shape=record,label="http://dikb.org/o-scatter\led-molecular-aggregate/5e\lde027b-cdc3-45cd-a6f5-da6\leb11e021c\lscattered molecular aggre\lgate\lobo:OBI_0000576\l",color=blue]
g70 -> g6 [label="\lobo:RO_0000053\l"]
g70 -> g49 [label="\lobo:RO_0002351\l"]
g70 -> g65 [label="\lobo:RO_0000053\l"]
g71 [shape=record,label="http://purl.obolibrary.or\lg/obo/IAO_0000109\l\lrdfs:Class\l",color=blue]
g72 [shape=record,label="http://purl.obolibrary.or\lg/obo/DIDEO_00000050\l\lrdfs:Class\l",color=blue]
g73 [shape=record,label="http://purl.obolibrary.or\lg/obo/RO_0000053\l\lrdf:Property\l",color=blue]
}